UPDATE: Mizuho Initiates Coverage On Pfizer with Buy Rating, Announces $42 Price Target As Firm Sees 'products such as Eliquis, Xtandi, and Xeljanz helping "New Pfizer" drive 7%+ sales and 9%+ income CAGR from 2020-2025.'